<DOC>
	<DOC>NCT01698645</DOC>
	<brief_summary>National multicenter, prospective, observational study in cancer patients with chronic background pain and breakthrough pain to whom PecFent® has been prescribed under pragmatic condition by a specialist in the treatment of cancer pain conditions. • Study objectives include assessment of early treatment satisfaction.</brief_summary>
	<brief_title>Patient Satisfaction and Quality of Life Impact - PecFent®</brief_title>
	<detailed_description />
	<mesh_term>Breakthrough Pain</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<criteria>Adult (aged ≥18 years) with cancer Taking at least 60 mg of oral morphine sulfate or equivalent per day for chronic background pain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>quality of life</keyword>
	<keyword>PecFent</keyword>
	<keyword>Lazanda</keyword>
	<keyword>fentanyl</keyword>
	<keyword>intranasal</keyword>
	<keyword>breakthrough cancer pain</keyword>
</DOC>